Clinical observation on the treatment of chronic actinic dermatitis and solar dermatitis with C-dot nanoe

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200063015

Enrollment

Unknown

Registered

2022-08-27

Start date

2022-08-27

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic actinic dermatitis and solar dermatitis

Interventions

Group 1 :Oral Hydroxychloroquine Sulfate Tablets and Vitamin C Tablets

Group 2:Oral hydroxychloroquine sulfate tablets and vitamin C tablets + topical matrix without C-dot nanozyme cream

Group 3:Oral hydroxychloroquine sulfate tablets and vitamin C tablets + topical cream containing C-dot nanozyme

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-80 years old, gender is not limited; 2. The diagnosis is consistent with chronic actinic dermatitis or solar dermatitis; 3. Good compliance, regular follow-up visits, and cooperation to complete this experiment; 4. Sign the informed consent form for external use of C-dot nanozyme cream and use it voluntarily.

Exclusion criteria

Exclusion criteria: 1. Combined with chronic heart failure, coronary heart disease and other cardiovascular diseases; 2. Combined with mental retardation and cognitive dysfunction; 3. Solar dermatitis patients with systemic symptoms, including fever, chills, headache, fatigue, nausea and general malaise, as well as palpitations, delirium or shock; 4. Patients with chronic actinic dermatitis with systemic symptoms; those with erythroderma; those who develop skin T lymphocyte tumor; 5. Previous history of alcoholism and drug abuse; 6. Has been treated in other hospitals and transferred to our hospital; 7. Pregnant women and lactating women; 8. Combined with severe infection and other serious skin diseases; 9. Patients who quit halfway or did not follow the established experimental plan for some reason; 10. Other circumstances in which the researcher considers it inappropriate to participate in the trial.

Design outcomes

Primary

Measure	Time frame
Clinical symptoms;Efficacy criteria;Dermatology life quality index;	—

Countries

Cina

Contacts

Public ContactZeng Weihui

The Second Affiliated Hospital of Xi'an Jiaotong University

zengwh88@126.com+86 13991161588

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026